Targeted Radionuclide Tumor Therapy

Dear Colleagues,

In the era of personalized cancer treatment there has been a great emphasis on targeted therapy. Targeted radionuclide therapy represents a promising therapeutic strategy for the treatment of patients with disseminated cancer. The success of targeted radionuclide therapy in malignant lymphomas has proven that this approach is feasible, effective and clinically translatable. However, the full translation of this approach to solid tumours was restricted by low tumour accumulation, normal tissue toxicity and an intrinsically greater radioresistance. There has recently been progress in the treatment of solid tumours with targeted radionuclide therapy, particularly in patients with somatostatin receptor-positive neuroendocrine tumours. This has opened the door to the development of new radionuclide-based targeting agents with therapeutic potential. As stated, the development of new targeted radionuclide therapies and their translation into clinical practice represents a great challenge in the field. This Special Issue has the aim of highlighting current progress in the development of potential targeting agents for targeted radionuclide therapy.

Prof. Vladimir Tolmachev
Dr. Mohamed Altai
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.